Occurrence of Malignancies Other than Breast and Ovarian Cancer in Female Carriers of a BRCA1/2 Germline Pathogenic Variant
If confirmed in larger, prospective studies that include the role of bias and previous cancer treatment, awareness of the possible increased risks of head and neck, gastrointestinal, and female genital cancer may be used to tailor clinical guidelines for female <i>BRCA1/2</i> GPV carriers.
Authors
- Marian J.E. Mourits (ORCID: https://orcid.org/0000-0003-2385-2639)
- Bert van der Vegt (ORCID: https://orcid.org/0000-0002-2613-1506)
- Annechien Stuursma (ORCID: https://orcid.org/0000-0001-9114-1797)
- Lieke P. V. Berger (ORCID: https://orcid.org/0000-0003-3185-559X)
- Geertruida H. de Bock (ORCID: https://orcid.org/0000-0003-3104-4471)
- Maaike B. C. ten Hoor (ORCID: https://orcid.org/0009-0004-3967-8027)
- Jan C. Oosterwijk
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
Publication Details
- Journal
- Cancers
- Published
- 2025-05-17
- DOI
- https://doi.org/10.3390/cancers17101687
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitair Medisch Centrum Groningen